The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Armstrong, Andrew Richard ^a,b   Herrmann, Susan Elizabeth ^c   Chassany, Olivier ^a,d   Lalanne, Christophe ^a   Da Silva, Mariliza Henrique ^e   Galano, Eliana ^e   Carrieri, Patrizia M ^f   Estellon, Vincent ^g   Sogni, Philippe ^h   Duracinsky, Martin ^a,d,i  

^a Lariboisière Hospital   (France)

^b AUSTRALIAN INSTITUTE OF FAMILY STUDIES   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d HÔTEL DIEU   (France)

^e HIV AIDS Reference and Treatment Center in São Paulo   (Brazil)

^f INSERM   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Institut Cochin   (France)

ⁱ BICÊTRE HOSPITAL   (France)

Author keywords

Health status; Hepatitis c; Quality of life; Questionnaires; Research methods

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; PEGINTERFERON; RIBAVIRIN; SEDATIVE AGENT;

ADULT; ARTICLE; AUSTRALIA; BRAZIL; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; DISTRESS SYNDROME; FATIGUE; FEAR; FEMALE; FRANCE; HEALTH STATUS; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERNATIONAL COOPERATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL SPECIALIST; MENTAL HEALTH; PAIN; PATIENT ATTITUDE; PATIENT REPORTED OUTCOME QUALITY OF LIFE; PHYSICAL ACTIVITY; PILOT STUDY; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP PARAMETERS; SOCIAL BEHAVIOR; SOCIAL PSYCHOLOGY; SOCIAL STIGMA; SOCIAL SUPPORT; SUBSTANCE USE; TREATMENT FAILURE; VALIDITY; HEALTH STATUS INDICATOR; HEPACIVIRUS; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; PSYCHOMETRY; STANDARDS; VALIDATION STUDY;

ADULT; AUSTRALIA; BRAZIL; FATIGUE; FEMALE; FRANCE; HEALTH STATUS INDICATORS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHOMETRICS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84988663820     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1771-0     Document Type: Article

References (33)

1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850-8.
2. Dolan K, Teutsch S, Scheuer N, Levy M, Rawlinson W, Kaldor J, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol. 2010;25:143-8.
3. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis. 2005;41:395-402.
4. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46 Suppl 5:S186-96.
5. Trembling PM, Tanwar S, Dusheiko GM. Protease inhibitors for chronic hepatitis C: Management of side effects. Hot Topics in Viral Hepatitis 2012;25:19-26.
6. Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology 2015;61(5):1471-8. doi: 10.1002/hep.27757.
7. Dore GJ, Lawitz E, Hezode C, Shafran SD, Ramji A, Tatum HA, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015;148:355-66. e351.
8. Thomas DL. Cure of hepatitis C virus infection without interferon alfa: Scientific basis and current clinical evidence. Top Antivir Med. 2014;21:152-6.
9. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Vir Hepatol. 2014;21 Suppl 1:1-4.
10. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.
11. Kleinman L, Mannix S, Yuan Y, Kummer S, L'Italien G, Revicki D. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes. 2012;10:92.
12. Danoff A, Khan O, Wan DW, Hurst L, Cohen D, Tenner CT, et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol. 2006;101:1235-43.
13. Moore GA, Hawley DA, Bradley P. Hepatitis C: Experiencing stigma. Gastroenterol Nurs. 2009;32:94-104.
14. Gillis J, Cooper C, Rourke S, Rueda S, O'Brien K, Collins E, et al. Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Qual Life Res. 2013;22:1525-35.
15. Kinder M. The lived experience of treatment for hepatitis C. Gastroenterol Nurs. 2009;32:401-8.
16. Janke EA, McGraw S, Garcia-Tsao G, Fraenkel L. Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics. 2008;49:494-501.
17. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-16.
18. Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument. Qual Life Res. 2014;23:561-70.
19. Anderson RT, Baran RW, Erickson P, Revicki DA, Dietz B, Gooch K. Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: Validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res. 2014;23:877-86.
20. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware Jr JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res. 1998;7:39-55.
21. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295-300.
22. Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, et al. Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease - The LDQOL 1.0. Am J Gastroenterol. 2000;95:3552-65.
23. van der Plas SM, Hansen BE, Boer JBD, Stijnen T, Passchier J, Man RAD, et al. The Liver Disease Symptom Index 2.0; Validation of a disease-specific questionnaire. Qual Life Res. 2004;13:1469-81.
24. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the European Regulatory Issues on Quality of Life Assessment (ERIQA) group. Patient-Reported Outcomes: The Example of Health-Related Quality of Life - A European guidance document for the improved integration of Health-Related Quality of Life assessment in the drug approval process. Drug Inf J. 2002;36:209-38.
25. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Patient Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 28 Apr 2016
26. Glaser B, Strauss A. The Discovery of Grounded Theory: Strategies for Qualitative Research. Chicago: Aldine Publishing Co; 1967.
27. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54 Suppl 1:S77-90.
28. Adler NE, Stewart J, with the Psychosocial Research Group. The MacArthur scale of subjective social status 2009. www.macses.ucsf.edu/research/psychosocial/subjective.php. Accessed 28 Apr 2016
29. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA. 1995;273(1):59-65.
30. Reflection Paper on Health-Related Quality of Life in the Evaluation of Medicinal Products. European Medicines Agency (EMA), 2006. www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003637. Accessed 28 Apr 2016
31. Lalanne C, Chassany O, Carrieri P, Marcellin F, Armstrong AR, Lert F, Spire B, Dray-Spira R, Duracinsky M. A reduced factor structure for the PROQOL-HIV questionnaire provided reliable indicators of health-related quality of life. J Clin Epidemiol. 2015;72:116-25.
32. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497-520.
33. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of perfectovir. Clin Infect Dis 2015;60(12):1829-36. doi: 10.1093/cid/civ197.